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Previous  studies  have  revealed  the  clinical  relevance  of  pro-inﬂammatory  cytokine  production  during
dengue virus  (DENV)  infections.  In this  study, we  evaluated  the  production  of  interleukin-21  (IL-21),  a
key soluble  mediator  mainly  produced  by CD4+  T cells.
The  aim  of  this  study  was  to investigate  the  role  of  IL-21  production  during  the  clinical  course  of
primary  and  secondary  DENV  infections  and  the potential  association  of  IL-21  serum  levels  with  the
disease  pathogenesis.  Blood  samples  from  DENV-infected  patients  were  collected  on different  days  after
the onset  of symptoms.  Patients  were  classiﬁed  according  to their  phase  of  disease  (acute  vs. convalescent
phases),  the  type  of  infection  (primary  vs. secondary),  and the  clinical  severity  of  their  disease  (dengue
fever  (DF)  vs.  dengue  hemorrhagic  fever  (DHF)).  IL-21  levels  were  measured  using  a  quantitative  capture
ELISA assay.  The  levels  of  IL-21  were  signiﬁcantly  elevated  in the disease  group  compared  with  the
control  group.  IL-21  was  detected  in  primary  and  secondary  DENV  infections,  with  a signiﬁcantly  higher
concentration  in  the convalescent  phase  of primary  infections.  IL-21  levels  were  signiﬁcantly  higher
in  patients  with  secondary  acute  DHF  infections  when  compared  with  those  with  secondary  acute DF
infection.  There  was  a relationship  between  the  elevated  serum  levels  of  IL-21 and  the  production  of
DENV-speciﬁc  IgM and  IgG antibodies.  Taking  together,  our  results  show  for the  ﬁrst  time  the  involvement
of IL-21  during  the clinical  course  of DENV  infections.
We  speculate  that IL-21  may  play  a protective  role  in the context  of  the  convalescent  phase  of primary
infections  and  the  acute  phase  of  secondary  infections.
ublis©  2014  The  Authors.  P
. Introduction
Dengue fever is the most common transmitted arboviral disease
orldwide. The infection is caused by one of the four serotypes
f dengue virus, the etiologic agents, all of which are members of
he Flavivirus group into the family Flaviviridae [1]. The pathophy-
iology of DF/DHF/DSS in humans is complex and multi-factorial,
nvolving the interplay of host and viral factors that inﬂuence dis-
ase severity and the clinical outcome [2]. With respect to host
actors, the immune response to DENV plays a dual role in terms
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165-2478/© 2014 The Authors. Published by Elsevier B.V. This is an open access article unhed  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
of both protection and the pathogenesis of the severe forms of this
viral disease. A cascade of pro-inﬂammatory cytokines is released
during acute dengue infections, including cytokines from innate
immunity cell sources, such as TNF-, IL-1, IL-6, and IFN-, and
chemokines, such as MIP1-,  IP-10 and IL-8. Pro-inﬂammatory
cytokines are implicated in host protection roles such as activat-
ing innate and adaptive immune cells, chemotaxis and inhibition of
viral replication. Some detrimental roles for the high inﬂammatory
cytokine levels that are often observed in severe disease include the
induction of cell death (apoptosis and necrosis), endothelial activa-
tion, vascular leak and shock [3–7]. Cytokines produced by adaptive
immune cells, such as CD4+ and CD8+ T cells, also play a major role
with respect to viral spread and further support the development
of effector functions, including humoral, cell-speciﬁc and memory
immune responses. During the CD4+ T cell response to DENV, Th1
and Th2 cells participate in the viral disease with the production
of IFN-, TNF-, and IL-2 or IL-4, IL-5, IL-6 and IL-10, respectively
[8]. A shift from the Th1 to Th2 response has been suggested in the
der the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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linical pathogenesis of DHF on the basis of in vitro studies and the
x vivo analysis of the cytokine patterns in the serum samples of
atients with severe disease [5,8–10].
In this study, we evaluated the interleukin-21 (IL-21) produc-
ion in sera from DENV infected patients, a key pro-inﬂammatory
nd soluble mediator mainly produced by CD4+ T cells. To date,
L-21 has not previously been studied during the clinical course
f DENV infections. IL-21 is a cytokine member of the common -
hain family, which includes IL-2, IL-4, IL-7, IL-9 and IL-15 [11].
L-21 is produced by various subsets of activated CD4+ T cells,
hich include Th17 cells, T-follicular helper (Tfh) and CD4+ natu-
al killer (NK) T cells, and exerts multiple and pleiotropic effects on
arious innate and adaptive immune cells, such as NK cells, mono-
ytes, macrophages, B cells, and CD4+ and CD8+ T lymphocytes,
s well as on non-immune cells such as keratinocytes [12], ﬁbro-
lasts [13,14] and vascular endothelial cells [15]. The aim of this
ork was to investigate whether the serum levels of IL-21 are ele-
ated in dengue-infected patients, analyzing the production during
rimary and secondary infections in comparison with healthy indi-
iduals and the potential association of IL-21 serum levels with the
isease pathogenesis.
. Materials and methods
.1. Subjects
A clinical cohort of patients with suspected cases of dengue
ere recruited in the city of Veracruz México during outbreaks that
ccurred from June 2010 through November 2012. A total of 360
ebrile patients were laboratory conﬁrmed for dengue infection and
nrolled in our study. Blood samples from patients were collected
n three urban health centers (“Anastasio Iturralde”, “21 de Abril”,
nd “El Coyol”), Hospital Regional de Alta Especialidad de Veracruz
nd Hospital Naval de Veracruz. Dengue patients had not received
ny drug or treatments before the sample collection. Blood samples
ere tested and diagnosed by reverse transcription-polymerase
hain reaction (RT-PCR) and ELISA techniques to conﬁrm the cases.
o rule out other viral or bacterial infections, further serological
ests for leptospirosis, inﬂuenza A, hepatitis A and Salmonella typhi
ere carried out at the clinical admission time. Patients were classi-
ed as having dengue fever or dengue hemorrhagic fever according
o clinical and laboratory criteria of the World Health Organiza-
ion (WHO 1997). Clinical case deﬁnition of dengue fever included
n acute febrile illness with two or more of the following mani-
estations: headache, retro-orbital pain, arthralgia, myalgia, rash,
eukopenia and supportive molecular or serology diagnosis. Clin-
cal case deﬁnition of dengue hemorrhagic fever included all of
he above criteria for DF plus evidence of hemorrhagic tenden-
ies (epistaxis, gingival bleeding, petechiae, a positive tourniquet
est). Vascular leakages were documented by chest X-ray and esti-
ating hypovolemia from multiple hematocrit determinations.
ther clinical and laboratory ﬁndings included thrombocytopenia
<100,000 counts/mm3), hypotension and hypoproteinemia. No
atal cases were included in the present study.
Seventy-eight serum samples from healthy individuals without
linical signs or manifestations suggestive of dengue (no febrile
ymptoms) or other apparent illnesses in the previous 3 months
ere included as controls. All serum samples were frozen at −70 ◦C
ntil analysis.
.2. Ethics statementWritten consent to participate in the study was obtained from
ach participant after a full explanation of the study was  provided
nd in accordance with the guidelines of the Ethics Committeey Letters 161 (2014) 89–95
of the Instituto de Investigaciones Medico-Biológicas, Universidad
Veracruzana (Veracruz, México). The study protocol was  approved
by the institutional ethics review board.
2.3. Dengue diagnosis
Serum samples were tested and diagnosed by reverse
transcription-polymerase chain reaction (RT-PCR) and three refer-
ence anti-dengue enzyme-linked immunosorbent assays (ELISA):
Platelia Dengue NS1 Ag Test (BIORAD Laboratories, France), Dengue
IgM (Panbio, Australia) and, to discriminate among primary and
secondary infections, a commercial kit (capture IgG ELISA, Pan-
bio) that is used for the quantitative detection of elevated titers of
IgG antibodies to dengue virus in patients with secondary infection
according to previously established criteria [16].
2.4. Classiﬁcation of samples
Based on the time of clinical illness, we classiﬁed dengue
patients into acute (1–7 days after disease onset) and convales-
cent (samples collected on days 8–10 after disease onset) phases.
Primary dengue infection was deﬁned for patients with positive
results for RT-PCR, NS1 and/or IgM tests and negative IgG ELISA
results. Secondary dengue infection was deﬁned for IgG ELISA pos-
itive results (equivalent to a hemagglutination inhibition titer of
>2560) regardless of RT-PCR, NS1 and IgM results.
2.5. Measurement of serum IL-21 levels
The IL-21 concentrations in the sera from dengue-positive
patients and healthy controls were measured by sandwich ELISA
kit from PeproTech Inc. (Rocky Hill, NJ) according to the manufac-
turer’s instructions. The optical density at 405 nm with a reference
ﬁlter at 650 nm was  measured by using a microplate reader (Aware-
ness Technology Inc., Palm City, FL, USA).
2.6. Measurement of serum DENV-speciﬁc IgM and IgG levels
The serum samples from dengue-infected patients were tested
for DENV IgM and IgG antibodies by ELISA at a 1:100 dilution.
Polysorb 96-well microplates (Nalge Nunc International, Rochester,
NY) coated with recombinant antigens provided in the Dengue IgM
kit and the commercial kit capture IgG ELISA (Panbio, Australia)
were used to measure the DENV speciﬁc antibody levels. The serum
samples were incubated for 1 h at 37 ◦C. After incubation, serum
samples were removed, and horseradish peroxidase-conjugated
monoclonal anti-human IgM or IgG were added for 1 h at 37 ◦C, fol-
lowed by the addition of 3,3′,5′-tetramethyl benzidine chromogen
solution. One hundred microliters of Stop Solution was added to
each well plate. The antibodies levels of each serum samples were
represented as an index value, according to the manufacturer’s
instructions. The OD results were corrected by subtracting the
OD values of blank samples which are included in every test kit.
The ratio with a standard positive sample, the cut-off calibrator, is
expressed as an index value (IV). Index value is calculated dividing
the optical density of the sample by the cutoff value.
2.7. Statistical analysis
The data were represented as the means ± SD or as medians.
The Chi square test was used to compare categorical variables.
The non-parametric Kruskal–Wallis test was used to comparison
more than two  groups. Comparisons among each patient group
were performed using Dunn’s multiple comparison tests. Statis-
tical signiﬁcance between two individual groups was determined
with the Mann–Whitney U test using GraphPad Prism software V
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Table  1
Classiﬁcation of dengue patients according to phase and severity disease.
Phase Dengue fever
(n = 235)
Dengue hemorrhagic fever
(n = 125)
Primary
n (%)
Secondary
n (%)
Primary
n (%)
Secondary
n (%)
Acute 71 (75.5%) 100 (70.9%) 20 (71.4%) 49 (50.5%)
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Total  (n) 94 141 
.0. P values <0.05 were considered statistically signiﬁcant. Correla-
ion between IL-21 and Dengue IgM and IgG levels among different
roups was evaluated using Spearman’s correlation test.
. Results
.1. Patient characteristics
The mean age of dengue patients was 29.9 years-old (range:
–74 years-old). The gender ratio was 1:1.6 (male: female). From
he 360 dengue-positive patients, 235 (65.28%) and 125 (34.72%)
ere classiﬁed as having DF and DHF, respectively, accordingly
o the World Health Organization clinical criteria (WHO 1997)
escribed before. DHF Patients were clinically managed in the
ospital for a median of 4 days. All DHF patients had laboratory
vidence of a rising hematocrit (evidence of plasma leakage) and
hrombocytopenia (<100,000 counts/mm3). 122 patients were con-
rmed to have primary dengue infection, and 238 were conﬁrmed
o have secondary dengue infections, following the laboratory crite-
ia described in the materials and methods section. Based on the
ime of clinical illness, a total of 240 patients were classiﬁed in the
cute phase (days 1–7 after disease onset) and 120 patients were
lassiﬁed in the convalescent phase (days 8–10 after disease onset)
Table 1).
.2. The serum levels of IL-21 are increased in dengue-infected
atients compared with healthy controls
To investigate whether IL-21 is produced during DENV infection,
he serum levels of IL-21 were measured by enzyme immunoassay.
n a ﬁrst analysis, we observed very low serum levels of IL-21 in the
ealthy control group (mean 14.5 ± 59.4 pg/ml, median 1.6 pg/ml)
nd a higher and heterogeneous production of IL-21 in dengue-
nfected patients (mean 147.2 ± 200.4 pg/ml, median 83.37 pg/ml),
 < 0.0001, Fig. 1A.
ig. 1. The serum levels of IL-21 are elevated in dengue-infected patients. (A) IL-21 conce
DEN)  (n = 360). (B) Comparison of the serum levels of IL-21 in acute (n = 91) and convalesce
hases  (n = 89) of secondary dengue infections. Statistical conﬁdence was  analyzed in ﬁ
nalysis in ﬁgure B. The IL-21 levels are represent in pg/ml. **P < 0.01, ***P < 0.001, ****P
econdary), CS (convalescent secondary).8 (28.6%) 48 (49.5%)
28 97
3.3. The highest serum levels of IL-21 are produced during the
convalescent phase of primary infections
Next, the serum levels of IL-21 were analyzed after classi-
fying all dengue patients according to their clinical evolution
(acute and convalescent phases) and type of infection (primary
or secondary). Interestingly, we observed that IL-21 was  signiﬁ-
cantly elevated during the convalescent phase of primary infections
(mean 230.5 ± 225.6 pg/ml, median 167.4 pg/ml) compared with
acute primary infections (mean 108.8 ± 152.2 pg/ml, median
74.56 pg/ml), acute secondary infections (mean 160 ± 226.9 pg/ml,
median 72.58 pg/ml), and convalescent secondary infections (mean
136.1 ± 178.3 pg/ml, median 86.4 pg/ml), Fig. 1B.
3.4. The stratiﬁcation of dengue-infected patients according to
the IL-21 concentrations, clinical phase and type of infection
Given the previous ﬁndings about the heterogeneity in the con-
centrations of IL-21 detected among patients, we were interested
in determining how the clinical stage of infection can inﬂuence the
production pattern for this cytokine. Thus, we stratiﬁed all of the
patients into three categories based on their IL-21 serum concen-
trations. Patients were classiﬁed in tertiles as low, medium, and
high IL-21 producers. The cutoff values for each category were set
considering the mean value for the healthy controls group plus one
or two  standard deviations. Concentrations below the ﬁrst cutoff
(≤73.9 pg/ml) were classiﬁed as low IL-21 producers. Concentra-
tions between the ﬁrst and second cutoff (74–133.3 pg/ml) were
classiﬁed as medium IL-21 producers, and concentrations above the
second cutoff (≥133.4 pg/ml) were classiﬁed as high IL-21 produc-
ers. We  related these categories with the type of infection (primary
or secondary) and the course of the disease (acute or convalescent
phases). A high percent (61.3%) of patients with primary infections
in the convalescent phase produced the highest levels of IL-21. High
concentrations of IL-21 were also detected in 40.3% of patients with
secondary infections in the acute phase. In contrast, 1.3% of the
ntrations in the sera of healthy controls (HC) (n = 78) and dengue-infected patients
nt phases (n = 31) of primary dengue infections vs. acute (n = 149) and convalescent
gure A by Mann–Whitney U test. The Kruskall–Wallis test was used for statistical
 < 0.0001. Abbreviations: AP (acute primary), CP (convalescent primary), AS (acute
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Table  2
Stratiﬁed analysis of IL-21 levels in dengue-infected patients, according to the clinical stage and the type of infection.
IL-21 production AP
n (%)
CP
n (%)
AS
n (%)
CS
n (%)
HC
n (%)
P value
Low 45 (49.5%) 7 (22.6%) 75 (50.3%) 40 (44.9%) 76 (97.4%) <0.0001
Medium 20 (22.0%) 5 (16.1%) 14 (9.4%) 19 (21.4%) 1 (1.3%) 0.0001
High  26 (28.5%) 19 (61.3%) 60 (40.3%) 30 (33.7%) 1 (1.3%) <0.0001
Total  (n) 91 31 149 89 78
L
A ent secondary, HC = healthy controls.
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Fig. 2. The serum levels of IL-21 and clinical disease severity. (A) IL-21 levels in
patients with dengue fever (DF) (n = 235), dengue hemorrhagic fever (DHF) (n = 125)
and healthy controls (HC) (n = 78). (B) Comparison of IL-21 levels in patients with
secondary acute DF infections (n = 100) and secondary acute DHF infections (n = 49).
(C) Comparison of IL-21 levels in patients with secondary convalescent DF infectionsow 0–73.9 pg/ml, medium 74–133.3 pg/ml, high >133.3 pg/ml.
P  = acute primary, CP = convalescent primary, AS = acute secondary, CS = convalesc
ealthy controls were classiﬁed as high IL-21 producers, whereas
7.4% of the control group was classiﬁed as low IL-21 producers
Table 2).
.5. The serum levels of IL-21 are associated with the severity of
engue infection during the acute phase of secondary infections
To evaluate whether there was a relationship among the het-
rogeneity in the serum concentrations of IL-21 and the severity
f disease, we grouped the patients into two groups based on their
linical classiﬁcation as DF or DHF. There was a trend toward higher
L-21 serum levels in DHF patients with respect to DF patients.
owever, in this ﬁrst analysis, there was no statistically signiﬁ-
ant difference between the groups (P > 0.05, Fig. 2A). Next, we
ecided to analyze the sample in more detail by comparing among
he same clinical stages. Because almost 80% of the DHF cases
ecruited in our study correspond to secondary infections, we com-
ared the serum levels of IL-21 considering just the cases of DF
nd DHF classiﬁed within the secondary infection group (Fig. 2B
nd C). As shown in Fig. 2B, IL-21 was signiﬁcantly elevated in the
erum of DHF patients during the acute phase of secondary infec-
ions (mean 165 ± 259.1 pg/ml, median 131.8 pg/ml) compared
ith DF patients in the acute phase of secondary infections (mean
49.6 ± 141.6 pg/ml, median 62.84 pg/ml; P = 0.02).
.6. The stratiﬁcation of dengue-infected patients according to
he IL-21 concentration, clinical phase and severity of disease
We  performed the same analysis as previously described in
able 2 to determine the distribution of DF or DHF patients stratiﬁed
y their IL-21 serum concentrations (Table 3). Interestingly, 49.0%
f DHF patients with secondary infections in the acute phase were
lassiﬁed as high IL-21 producer, 16.3% were classiﬁed as medium
roducers and 34.7% were classiﬁed as low IL-21 producers. In con-
rast, 36% of DF patients with secondary infections in the acute
hase were classiﬁed as high IL-21 producers, 6% were classiﬁed
s medium producers and 58% were classiﬁed as low IL-21 pro-
ucers. When we compared the convalescence phases of DF and
HF, we observed a similar distribution of the patients indepen-
ent of the severity of the disease. A remarkable result was  the
igh percentage of DF patients (60.9%) and DHF patients (62.5%) in
he convalescent phase of primary infections who  were classiﬁed
s high IL-21 producers.
.7. The serum IL-21 levels in dengue patients correlate with
ENV-speciﬁc IgM and IgG levels
Finally, we identiﬁed possible correlations between the serum
L-21 levels and the humoral response raised against DENV. The
trength of association between the serum IL-21 levels and the
nti-Dengue IgM or IgG levels were examined using the Spear-
an’s correlation test. Fig. 3 shows the scatter plots for the levels
f anti-dengue IgM and IgG against the serum IL-21 levels in
rimary and secondary dengue infections, respectively. Dengue(n = 41) and secondary convalescent DHF infections (n = 48). Statistical conﬁdence
was analyzed in ﬁgure A by Kruskall–Wallis test. Mann–Whitney U test was used
for  statistical analysis in ﬁgures B and C. The IL-21 levels are represent in pg/ml.
*P  < 0.05, ****P < 0.0001.patients in the acute phase of primary infections, days 1–7 showed
undetectable or low levels of DEN-speciﬁc IgM antibodies (IgM
ratio, 2.052 ± 2.641) with no signiﬁcant correlation values with
the serum IL-21 levels (Fig. 3A). The levels of dengue-speciﬁc IgM
H. Vivanco-Cid et al. / Immunology Letters 161 (2014) 89–95 93
Table  3
Stratiﬁed analysis of IL-21 levels in dengue fever and dengue hemorrhagic fever patients, according to the clinical stage and the type of infection.
IL-21 production AP
n (%)
CP
n (%)
AS
n (%)
CS
n (%)
HC
n (%)
P value
Dengue fever patients
Low 36 (50.7%) 5 (21.7%) 58 (58.0%) 19 (46.3%) 76 (97.4%) <0.0001
Medium 13 (18.3%) 4 (17.4%) 6 (6.0%) 8 (19.5%) 1 (1.3%) 0.002
High  22 (31.0%) 14 (60.9%) 36 (36.0%) 14 (34.2%) 1 (1.3%) <0.0001
Total  (n) 71 23 100 41 78
Dengue hemorrhagic fever patients
Low 9 (45.0%) 2 (25%) 17 (34.7%) 21 (43.8%) 76 (97.4%) <0.0001
Medium 7 (35.0%) 1 (12.5%) 8 (16.3%) 11 (22.9%) 1 (1.3%) 0.003
High  4 (20%) 5 (62.5%) 24 (49.0%) 16 (33.3%) 1 (1.3%) <0.0001
Total  (n) 20 8 49 48 78
Low 0–73.9 pg/ml, medium 74–133.3 pg/ml, high >133.3 pg/ml.
AP  = acute primary, CP = convalescent primary, AS = acute secondary, CS = convalescent secondary, HC = healthy controls.
Fig. 3. Correlation between the Dengue-speciﬁc IgM antibodies levels and the IL-21 serum levels in the acute (A) or convalescent phases (B) of primary dengue infections.
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ihe  serum levels of IL-21 were signiﬁcantly and positively correlated with the incr
rimary infections. Correlation between the Dengue-speciﬁc IgG antibodies levels a
nfections. A signiﬁcant and positive correlation between the serum levels of IL-21 
 < 0.0097). Each dot represents one subject.
ntibodies increase in the convalescent phase of primary infec-
ions, on days 8–10 to a mean ratio of 4.598 ± 2.599. The serum
evels of IL-21 were signiﬁcantly and positively correlated with the
ncrease of anti-dengue IgM levels (r = 0.4260, P < 0.0189) in the
onvalescent phase of primary infections (Fig. 3B). For secondary
nfections we found a signiﬁcant and positive correlation between
he serum levels of IL-21 and the increase of anti-dengue IgG lev-
ls (IgG ratio, 5.818 ± 1.881) during the acute phase (r = 0.2928,
 < 0.0097) (Fig. 3C). However, no signiﬁcant correlation value was
ound between dengue-IgG levels and the serum levels of IL-21
uring the convalescent phase of secondary infections (r = 0.2110,
 < 0.1026) (Fig. 3D).. Discussion
Cytokine levels differ dramatically from steady state conditions
n healthy controls compared with patients exhibiting activeof anti-dengue IgM levels (r = 0.4260, P < 0.0189), just in the convalescent phase of
 IL-21 serum levels in the acute (C) or convalescent phases (D) of secondary dengue
e increase of anti-dengue IgG levels was  found during the acute phase (r = 0.2928,
disease. In dengue infections, there is a highly heterogeneous host
immune response to the viral infection depending of the severity of
the disease. Here, we present for the ﬁrst time evidence of IL-21 pro-
duction during dengue infections. It is apparent from our ﬁndings
that the levels of IL-21 increase signiﬁcantly during DENV infection
compared with the levels in healthy individuals. In our study, the
highest IL-21 concentrations were measured in patients during
the convalescence phase of primary infections. This particular pro-
duction pattern of IL-21 was demonstrated for both clinical forms:
DF and DHF. A high percent of DF (60.9%) and DHF patients (62.5%)
in the convalescent phase of primary infections were classiﬁed as
the highest IL-21 producers. Interestingly, we found in the same
clinical stage that the serum IL-21 levels correlated well with the
DENV-speciﬁc IgM production. These observations are consistent
with the role IL-21 plays in plasma cell differentiation [17].
High IL-21 levels during the convalescent phase correlate well
with the time when the dengue-infected patients began to recover.
9 nolog
T
b
o
t
a
s
t
[
[
c
m
m
i
P
t
s
t
o
p
t
s
m
o
i
a
v
h
B
a
l
i
l
H
t
b
i
v
A
a
i
i
t
s
t
t
o
t
a
i
s
t
I
i
m
i
p
T
p
I
I
[
r
o
b
levels of tumor necrosis factor-alpha (TNF-alpha), interleukin-6 (IL-6), and
interleukin-1 beta (IL-1 beta) in dengue-infected patients. Am J Trop Med  Hyg4 H. Vivanco-Cid et al. / Immu
he recovery phase is characterized by improving general well
eing and hemodynamic stability, which suggest a protective role
f this cytokine in this clinical stage of primary infections. Fur-
hermore, during the acute phase of secondary dengue infections,
 positive correlation between the serum IL-21 levels and DENV-
peciﬁc IgG levels was found. This association also is consistent with
he critical role IL-21 plays as a potent inducer of IgG production
18–20] and promoting the activation of memory B cells by T cells
17].
Because of the cellular-restricted origins of IL-21, this cytokine
ould be considered a good potential biomarker of the protection
ediated by CD4+ T or NKT cells against dengue virus in pri-
ary infections. Interestingly, a recent study has identiﬁed that an
mportant proportion of DENV-speciﬁc CD4+ T cells isolated from
BMCs from convalescent dengue virus patients displayed a pheno-
ype characteristic of circulating follicular helper T cells (TFH cells),
uggesting that they are interacting with B cells in vivo [21]. A frac-
ion of DENV-speciﬁc CXCR5+ cells was capable of producing IL-21
r IFN- following stimulation with DENV peptides. The evidence
rovided by Rivino et al., and our own results, support the idea
hat a fraction of DENV-speciﬁc CD4+ T cells could be involved in
upporting B cell antibody production through an IL-21 dependent
echanism.
The biological effects and clinical relevance of the production
f IL-21 in primary dengue infections could be related to the
mportance of IL-21 in the acute phase to enhance the cytotoxic
ctivity of NK cells and establish viral control early. In the con-
alescence phase, IL-21 could be very important to support the
umoral response through the proliferation and differentiation of
 cells into plasma cells, enhancing immunoglobulin production
nd isotype class switch and promoting the activation of cellu-
ar responses mediated by CD8+ T cells and the development of
mmunological memory. Clinical and basic research has estab-
ished the protective role of IL-21 in other viral diseases, including
IV [22–25], HBV [26], herpes simplex virus [27], and respira-
ory syncytial virus [28]. Recently, a protective role for IL-21 has
een demonstrated during the course of the chronic Hepatitis C
nfections in humans [29]. Hepatitis C virus is a member of the Fla-
iviridae family and is closely related to the dengue fever virus.
lthough IL-21 has been mainly associated with protective roles
nd sustaining T cell responses during chronic viral infections, little
s known about the role of this cytokine in the course of acute viral
nfections such as dengue. The role of IL-21 during secondary infec-
ion by DENV is more intriguing than in primary infections. In our
tudy, IL-21 levels indeed were signiﬁcantly higher in DHF patients
han in patients with DF in the acute phase of secondary infec-
ions. However, the higher levels of IL-21 in secondary infections
f DHF patients compared to DF patients probably are a reﬂec-
ion of the more intense immune activation in DHF rather than
 cause of the severity of disease. It is well known that secondary
nfections with a distinct DENV serotype led to the activation of
erotype-cross-reactive T cells, resulting in elevated levels of adap-
ive immune response-derived cytokines such as IFN-, IL-2, IL-4,
L-10 and TNF-, which have been reported to be more pronounced
n DHF compared to DF in some studies [30–32]. A potential detri-
ental role for IL-21 during the acute phase of DHF secondary
nfections could be through the activation of different immune cell
opulations, such as monocytes, macrophages, dendritic cells and
 cells. IL-21 has been reported to induce the production of many
ro-inﬂammatory cytokines, such as GM-CSF, IL-1, IL-2, IL-7, IL-15,
FN-, and chemokines, such as IL-8, RANTES, MIP-1,  Eotaxin, and
P-10, by human NK cells [33,34], monocytes [35], macrophages
36], dendritic cells [37] and T cells [38–40]. Although the IL-21
eceptor is expressed on vascular endothelial cells, a direct effect
f this cytokine on vascular activation and vascular leakage has not
een reported.y Letters 161 (2014) 89–95
5. Conclusions
Here, we report for the ﬁrst time the role of IL-21 during the
clinical course of DENV infections. Our present study is the ﬁrst
to report that there is a relationship between the elevated serum
levels of IL-21 and the production of DENV-speciﬁc IgM and IgG
antibodies.
We  speculate that IL-21 may  play a protective role in the context
of the convalescent phase of primary infections and the acute phase
of secondary infections. Given the different biological effects and
the pleiotropic activities of IL-21, our results open a very attractive
ﬁeld of study for this cytokine in a very complex infectious disease
such as dengue fever.
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